Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Arima Genomics Announces AACR 2026 Presentations Across Solid Tumors

By: Arima Genomics, Inc. via Business Wire

April 15, 2026 at 08:00 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Data from five presentations spanning lung, gastrointestinal, and gynecologic cancers highlight how structural variant analysis can expand what cancer genomics reveals

Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to advance cancer therapy selection, today announced that it will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, California. The five presentations will highlight the power of Arima’s Hi-C sequencing-based approach to detect clinically relevant structural variants and uncover important drivers of cancer across solid tumors. Together, they reflect Arima’s vision for expanding cancer genomics beyond sequence alone.

“Structural variants are an important driver of cancer biology, and Arima is focused on bringing that dimension into cancer genomics,” said Anthony Schmitt, PhD, Senior Vice President of Science at Arima Genomics. “The data we will present at AACR reflect the breadth of that opportunity across solid tumors.”

The presentations include data demonstrating Arima’s ability to detect structural variants in lung and gastrointestinal tumors, showing concordance with traditional methods while also identifying variants those methods may miss. That capability, demonstrated across multiple studies, underpins Arima’s Aventa FusionPlus clinical assay. Additional presentations demonstrate the ability to detect and predict the functional impact of enhancer hijacking rearrangements and extrachromosomal DNA (ecDNA) amplifications in non-small cell lung cancer (NSCLC). A fifth presentation extends Arima’s work in fusion and rearrangement detection into gynecologic carcinosarcoma through analysis of aberrations involving genes potentially linked to homologous recombination deficiency (HRD). Together, the AACR data show the range of biological and clinical questions that a structural variant-focused approach can address.

“These studies show how Arima’s technology provides a new lens with which to view the cancer genome in a way that no other technology can,” said Tom Willis, PhD, Chief Executive Officer of Arima Genomics. “We are already putting this approach to work for patients through our Aventa clinical tests, while continuing to build the evidence and applications that support a more complete view of cancer.”

List of Poster Presentations

April 20, 2026, 2:00-5:00 PM

Detection and functional assessment of extrachromosomal DNA amplifications in FFPE lung tumor specimens using Hi-C sequencing

Poster Number: 3259
Location: Section 22

Discovery and functional characterization of enhancer hijacking oncogene rearrangements in NSCLC using Hi-C sequencing of FFPE tumors

Poster Number: 3747
Location: Section 41

Fusions and rearrangement detection in gastrointestinal and lung tumors leveraging low-pass whole-genome sequencing based Hi-C chemistry

Poster Number: 3817
Location: Section 44

Genome wide testing of archived ovarian and uterine carcinosarcoma FFPE tissue using FusionPlus Hi-C to determine HRD status

Poster Number: 3970
Location: Section 49

April 21, 2026, 2:00-5:00 PM

Actionable fusions and rearrangements can be efficiently identified by Hi-C whole genome sequencing in lung tumors

Poster Number: 6521
Location: Section 43

About Arima Genomics

Arima Genomics is redefining cancer diagnostics using whole-genome sequence and structure information. Arima’s assays enable a new era of comprehensive, clinically actionable therapy selection insights. The company serves oncologists through its CLIA-certified Aventa clinical testing laboratory in Orlando, Florida, and supports discovery-stage researchers worldwide with advanced kits and informatics. Learn more at www.arimagenomics.com and aventatest.com, and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260415098035/en/

Contacts

Media Contact
Rachel Ford Hutman
Rachel@fordhutmanmedia.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	238.55	-2.96 (-1.23%)
AAPL	291.13	-4.50 (-1.52%)
AMD	511.57	+23.12 (4.73%)
BAC	56.02	+0.86 (1.56%)
GOOG	358.16	+1.60 (0.45%)
META	566.98	-1.45 (-0.26%)
MSFT	390.74	+0.40 (0.10%)
NVDA	205.19	+0.32 (0.16%)
ORCL	184.13	+0.03 (0.02%)
TSLA	406.43	+7.28 (1.82%)